Franklin Street Advisors Upped Its Amazon.Com (AMZN) Holding; 5 Analysts Covering Ligand Pharmaceuticals (LGND)

Among 6 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Ligand Pharmaceuticals had 27 analyst reports since September 3, 2015 according to SRatingsIntel. Roth Capital maintained Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Friday, March 11 with “Buy” rating. The stock of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has “Buy” rating given on Wednesday, October 11 by Roth Capital. The firm has “Buy” rating given on Wednesday, November 15 by Craig Hallum. Deutsche Bank downgraded Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Monday, November 20 to “Sell” rating. TH Capital maintained it with “Buy” rating and $140 target in Wednesday, September 30 report. The firm has “Buy” rating by Roth Capital given on Monday, September 21. The company was maintained on Thursday, November 9 by H.C. Wainwright. On Wednesday, September 30 the stock rating was maintained by Roth Capital with “Buy”. Roth Capital maintained the shares of LGND in report on Friday, December 18 with “Buy” rating. On Wednesday, January 24 the stock rating was maintained by H.C. Wainwright with “Buy”. See Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) latest ratings:

26/02/2018 Broker: Roth Capital Rating: Buy New Target: $171.0 Maintain
22/02/2018 Broker: Craig Hallum Rating: Buy New Target: $190.0 Maintain
22/02/2018 Broker: Stephens Rating: Buy New Target: $162.0 Maintain
24/01/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy Old Target: $159 New Target: $170 Maintain
20/11/2017 Broker: Deutsche Bank Old Rating: Hold New Rating: Sell Old Target: $104 Downgrade
15/11/2017 Broker: Craig Hallum Rating: Buy New Target: $170.0 Maintain
13/11/2017 Broker: Roth Capital Rating: Buy New Target: $158.0 Maintain
09/11/2017 Broker: H.C. Wainwright Rating: Buy Old Target: $157 New Target: $159 Maintain
18/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $157.0 Maintain
11/10/2017 Broker: Roth Capital Rating: Buy New Target: $158.0 Maintain

Franklin Street Advisors Inc increased Amazon.Com Inc (AMZN) stake by 10.62% reported in 2017Q3 SEC filing. Franklin Street Advisors Inc acquired 1,108 shares as Amazon.Com Inc (AMZN)’s stock rose 13.58%. The Franklin Street Advisors Inc holds 11,537 shares with $11.09M value, up from 10,429 last quarter. Amazon.Com Inc now has $726.28 billion valuation. The stock increased 0.46% or $6.8 during the last trading session, reaching $1500.25. About 6.59M shares traded or 34.16% up from the average. Amazon.com, Inc. (NASDAQ:AMZN) has risen 37.41% since March 4, 2017 and is uptrending. It has outperformed by 20.71% the S&P500.

The stock increased 2.89% or $4.47 during the last trading session, reaching $159.01. About 387,305 shares traded or 53.76% up from the average. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has declined 2.87% since March 4, 2017 and is downtrending. It has underperformed by 19.57% the S&P500.

Investors sentiment increased to 1.69 in Q3 2017. Its up 0.45, from 1.24 in 2017Q2. It increased, as 19 investors sold Ligand Pharmaceuticals Incorporated shares while 68 reduced holdings. 50 funds opened positions while 97 raised stakes. 22.76 million shares or 0.86% more from 22.57 million shares in 2017Q2 were reported. Proshare Advsrs Limited Co invested in 0.02% or 14,170 shares. Cardinal Cap Management Ltd Liability Ct, a Connecticut-based fund reported 623,341 shares. Smith Asset Mgmt Group Limited Partnership invested in 3,920 shares. Ahl Prtnrs Limited Liability Partnership accumulated 8,162 shares. Portfolio Solutions Limited Liability Corporation reported 50 shares stake. Los Angeles Mgmt & Equity Rech invested in 0% or 1,692 shares. Moreover, Verity Asset Management has 0.29% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 2,604 shares. Fmr Llc has invested 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Matarin Capital Mngmt Limited Liability Corporation holds 0.31% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) or 26,827 shares. Asset invested 0.01% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). California Public Employees Retirement Systems accumulated 41,449 shares or 0.01% of the stock. Brinker invested in 0.01% or 1,734 shares. Amalgamated National Bank & Trust reported 0.01% stake. Whittier has 20 shares for 0% of their portfolio. New York-based Opus Point Mngmt Limited has invested 0.19% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND).

Since September 5, 2017, it had 0 buys, and 8 sales for $13.91 million activity. $3.71M worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was sold by HIGGINS JOHN L on Wednesday, January 24. On Friday, February 23 the insider FOEHR MATTHEW W sold $832,824. KOZARICH JOHN W sold $362,500 worth of stock. The insider Davis Todd C sold 17,170 shares worth $2.62M. Sabba Stephen L sold $126,956 worth of stock. The insider Aryeh Jason sold 3,417 shares worth $529,635.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company has market cap of $3.36 billion. The Company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. It has a 300.02 P/E ratio. The companyÂ’s partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others.

Investors sentiment decreased to 1.26 in Q3 2017. Its down 0.10, from 1.36 in 2017Q2. It turned negative, as 73 investors sold AMZN shares while 549 reduced holdings. 127 funds opened positions while 657 raised stakes. 279.77 million shares or 1.91% less from 285.20 million shares in 2017Q2 were reported. Guardian Cap LP has 0% invested in Amazon.com, Inc. (NASDAQ:AMZN). J&P(China)Capital Coltd stated it has 29,900 shares. Glenmede Tru Na has 0.07% invested in Amazon.com, Inc. (NASDAQ:AMZN) for 16,685 shares. David R Rahn Associate Inc has 1.86% invested in Amazon.com, Inc. (NASDAQ:AMZN) for 2,801 shares. Washington owns 36,874 shares. Accredited Incorporated reported 386 shares. Jag accumulated 2.94% or 16,333 shares. Columbia Pacific Advsrs Ltd holds 0.39% or 325 shares in its portfolio. Evercore Wealth, a New York-based fund reported 60,713 shares. Hilltop owns 446 shares. Blackhill Cap invested in 80 shares. Glynn Capital Llc stated it has 9.53% in Amazon.com, Inc. (NASDAQ:AMZN). Bancorp Of New York Mellon Corp has 4.02 million shares for 1.06% of their portfolio. Point72 Asset Management Ltd Partnership owns 291,304 shares or 1.25% of their US portfolio. Homrich & Berg holds 0.12% or 1,518 shares in its portfolio.

Since December 7, 2017, it had 0 buys, and 10 selling transactions for $42.36 million activity. 670 shares were sold by ALBERG TOM A, worth $1.01 million. The insider WILKE JEFFREY A sold $2.99M. Olsavsky Brian T had sold 2,333 shares worth $3.42M. The insider Jassy Andrew R sold $2.90M. Another trade for 12,666 shares valued at $18.50 million was sold by Blackburn Jeffrey M. On Thursday, February 15 Reynolds Shelley sold $795,502 worth of Amazon.com, Inc. (NASDAQ:AMZN) or 544 shares. $3.24 million worth of Amazon.com, Inc. (NASDAQ:AMZN) shares were sold by Zapolsky David.

Among 54 analysts covering Amazon.com (NASDAQ:AMZN), 51 have Buy rating, 0 Sell and 3 Hold. Therefore 94% are positive. Amazon.com has $2000.0 highest and $105 lowest target. $1386.37’s average target is -7.59% below currents $1500.25 stock price. Amazon.com had 277 analyst reports since July 21, 2015 according to SRatingsIntel. JMP Securities maintained it with “Market Outperform” rating and $1600 target in Friday, February 2 report. Mizuho maintained the shares of AMZN in report on Friday, April 29 with “Buy” rating. Piper Jaffray maintained the stock with “Buy” rating in Wednesday, July 12 report. The firm earned “Buy” rating on Friday, July 28 by Aegis Capital. The stock of Amazon.com, Inc. (NASDAQ:AMZN) has “Buy” rating given on Friday, September 30 by Guggenheim. On Friday, October 27 the stock rating was maintained by RBC Capital Markets with “Buy”. The stock of Amazon.com, Inc. (NASDAQ:AMZN) has “Hold” rating given on Friday, October 23 by Canaccord Genuity. Stifel Nicolaus maintained Amazon.com, Inc. (NASDAQ:AMZN) rating on Friday, February 2. Stifel Nicolaus has “Buy” rating and $1800.0 target. The stock of Amazon.com, Inc. (NASDAQ:AMZN) earned “Buy” rating by Citigroup on Friday, April 1. The stock has “Outperform” rating by Oppenheimer on Friday, October 27.

Franklin Street Advisors Inc decreased Waste Management Inc Del (NYSE:WM) stake by 5,063 shares to 96,228 valued at $7.53 million in 2017Q3. It also reduced Alphabet Inc Cap Stk Cl C stake by 909 shares and now owns 16,861 shares. Lockheed Martin Corp (NYSE:LMT) was reduced too.